VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025.
| Fireside Chat Presentation Details: | |
| Date: | Tuesday, June 10, 2025 |
| Time: | 3:20-3:55 PM Eastern Time |
| Webcast: | Register here |
| Presenter: | Ian Mortimer, President and Chief Executive Officer |
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$45.01 |
| Daily Change: | 0.40 0.90 |
| Daily Volume: | 399,160 |
| Market Cap: | US$3.480B |
December 05, 2025 December 03, 2025 November 25, 2025 November 06, 2025 November 03, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
